Skip to main content
Top
Published in: International Journal of Clinical Oncology 6/2020

01-06-2020 | Esophageal Cancer | Original Article

Comparison of involved field radiotherapy and elective nodal irradiation in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer

Authors: Yukihiro Nakatani, Ken Kato, Hirokazu Shoji, Satoru Iwasa, Yoshitaka Honma, Atsuo Takashima, Toshikazu Ushijima, Yoshinori Ito, Jun Itami, Narikazu Boku

Published in: International Journal of Clinical Oncology | Issue 6/2020

Login to get access

Abstract

Background

The optimal radiation field of chemoradiation therapy (CRT) for stage I esophageal squamous cell carcinoma (ESCC) is unknown. This retrospective study compared efficacy and safety of two CRT modalities, involved field irradiation (IFI) and elective nodal irradiation (ENI), when treating patients with clinical stage I (T1bN0M0) ESCC.

Methods

Patients had received 60 Gy CRT concurrently with 5-FU and cisplatin between January 2000 and December 2012. The clinical target volume of IFI was limited to the primary tumor plus a 2-cm craniocaudal margin; that of ENI covered the primary tumor plus the field of regional lymph nodes.

Results

One hundred and ninety-five patients were selected (IFI group, 78; ENI group, 117). The 5-year overall, cause-specific and progression-free survival rates were 90.5%, 91.6% and 77.6% in the IFI group, and 72.5%, 88.3%, 57.9% in the ENI group, respectively. Of recurrent patients (n = 16 in the IF and n = 33 in the ENI groups) after achieving complete remission, 12 (75%) in the IFI group received definitive salvage therapy, 11 (33%) patients did in the ENI group. More patients died of diseases other than esophageal cancer in the ENI group (n = 29, 25%) than in the IFI group (n = 3, 3.8%). Multivariate analysis identified ENI (HR 3.63 [1.78–7.38], p < 0.001), age ≥ 70 (HR 2.65 [1.53–4.58], p < 0.001) and PS = 1 (HR 2.36 [1.33–4.18], p = 0.003) as poor prognostic factors for OS.

Conclusions

IF irradiation would be better than ENI for the patients with stage I ESCC who received definitive chemoradiotherapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kitagawa Y, Uno T, Oyama T et al (2018) Esophageal cancer practice guidelines 2017 edited by the japan esophageal society: part 1. Esophagus 1:1–24CrossRef Kitagawa Y, Uno T, Oyama T et al (2018) Esophageal cancer practice guidelines 2017 edited by the japan esophageal society: part 1. Esophagus 1:1–24CrossRef
3.
go back to reference Kodama M, Kakegawa T (1998) Treatment of superficial cancer of the esophagus: a summary of responses to a questionnaire on superficial cancer of the esophagus in Japan. Surgery 123:432–439CrossRefPubMed Kodama M, Kakegawa T (1998) Treatment of superficial cancer of the esophagus: a summary of responses to a questionnaire on superficial cancer of the esophagus in Japan. Surgery 123:432–439CrossRefPubMed
4.
go back to reference Ito H, Itasaka S, Sakanaka K et al (2017) Long-term complications of definitive chemoradiotherapy for esophageal cancer using the classical method. J Radiat Res 58(1):106–113CrossRefPubMedPubMedCentral Ito H, Itasaka S, Sakanaka K et al (2017) Long-term complications of definitive chemoradiotherapy for esophageal cancer using the classical method. J Radiat Res 58(1):106–113CrossRefPubMedPubMedCentral
5.
go back to reference Wang X, Miao C, Chen Z et al (2017) Can involved-field irradiation replace elective nodal irradiation in chemoradiotherapy for esophageal cancer? A systematic review and meta-analysis. Oncol Targets Ther 10(5):2087–2095CrossRef Wang X, Miao C, Chen Z et al (2017) Can involved-field irradiation replace elective nodal irradiation in chemoradiotherapy for esophageal cancer? A systematic review and meta-analysis. Oncol Targets Ther 10(5):2087–2095CrossRef
6.
go back to reference Akutsu Y, Kato K, Igaki H et al (2016) The prevalence of overall and initial lymph node metastases in clinical T1N0 thoracic esophageal cancer from the results of JCOG0502, a prospective multicenter study. Ann Surg 264(6):1009–1015CrossRefPubMed Akutsu Y, Kato K, Igaki H et al (2016) The prevalence of overall and initial lymph node metastases in clinical T1N0 thoracic esophageal cancer from the results of JCOG0502, a prospective multicenter study. Ann Surg 264(6):1009–1015CrossRefPubMed
7.
go back to reference Gao XS, Qiao X, Wu F et al (2007) Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys 67(2):389–396CrossRefPubMed Gao XS, Qiao X, Wu F et al (2007) Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys 67(2):389–396CrossRefPubMed
8.
go back to reference Japan Esophageal Society (2017) Japanese classification of esophageal cancer, 11th edition: part II and III. Esophagus 14(1):37–65CrossRef Japan Esophageal Society (2017) Japanese classification of esophageal cancer, 11th edition: part II and III. Esophagus 14(1):37–65CrossRef
9.
go back to reference Minsky BD, Pajak TF, Ginsberg RJ et al (2002) INT0123 (radiation therapy oncology group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiotherapy. J Clin Oncol 20:1167–1174CrossRefPubMed Minsky BD, Pajak TF, Ginsberg RJ et al (2002) INT0123 (radiation therapy oncology group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiotherapy. J Clin Oncol 20:1167–1174CrossRefPubMed
10.
go back to reference Kato K, Nakajima TE, Ito Y et al (2013) Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for stage II–III esophageal carcinoma. Jpn J Clin Oncol 43(6):608–615CrossRefPubMed Kato K, Nakajima TE, Ito Y et al (2013) Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for stage II–III esophageal carcinoma. Jpn J Clin Oncol 43(6):608–615CrossRefPubMed
11.
go back to reference Onozawa M, Nihei K, Ishikura S et al (2009) Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. Radiother Oncol 92:266–269CrossRefPubMed Onozawa M, Nihei K, Ishikura S et al (2009) Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. Radiother Oncol 92:266–269CrossRefPubMed
12.
go back to reference Kawaguchi Y, Nishiyama K, Miyagi K et al (2011) Patterns of failure associated with involved field radiotherapy in patients with clinical stage I thoracic esophageal cancer. Jpn J Clin Oncol 41(8):1007–1012CrossRefPubMed Kawaguchi Y, Nishiyama K, Miyagi K et al (2011) Patterns of failure associated with involved field radiotherapy in patients with clinical stage I thoracic esophageal cancer. Jpn J Clin Oncol 41(8):1007–1012CrossRefPubMed
13.
go back to reference Ishikawa H, Sakurai H, Tamaki Y et al (2006) Radiation therapy alone for stage I (UICC T1N0M0) squamous cell carcinoma of the esophagus: indications for surgery or combined chemoradiotherapy. J Gastroenterol Hepatol 21(8):1290–1296CrossRefPubMed Ishikawa H, Sakurai H, Tamaki Y et al (2006) Radiation therapy alone for stage I (UICC T1N0M0) squamous cell carcinoma of the esophagus: indications for surgery or combined chemoradiotherapy. J Gastroenterol Hepatol 21(8):1290–1296CrossRefPubMed
14.
go back to reference Fukada J, Shigematsu N, Ohashi T et al (2012) Pericardial and pleural effusions after definitive radiotherapy for esophageal cancer. J Radiat Res 53:447–453CrossRefPubMed Fukada J, Shigematsu N, Ohashi T et al (2012) Pericardial and pleural effusions after definitive radiotherapy for esophageal cancer. J Radiat Res 53:447–453CrossRefPubMed
15.
go back to reference Ishikura S, Nihei K, Ohtsu A et al (2003) Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 21:2697–2702CrossRefPubMed Ishikura S, Nihei K, Ohtsu A et al (2003) Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 21:2697–2702CrossRefPubMed
16.
go back to reference Mackley HB, Adelstein JS, Reddy CA et al (2008) Choice of radiotherapy planning modality influences toxicity in the treatment of locally advanced esophageal cancer. J Gastrointest Cancer 39(1–4):130–137CrossRefPubMed Mackley HB, Adelstein JS, Reddy CA et al (2008) Choice of radiotherapy planning modality influences toxicity in the treatment of locally advanced esophageal cancer. J Gastrointest Cancer 39(1–4):130–137CrossRefPubMed
Metadata
Title
Comparison of involved field radiotherapy and elective nodal irradiation in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer
Authors
Yukihiro Nakatani
Ken Kato
Hirokazu Shoji
Satoru Iwasa
Yoshitaka Honma
Atsuo Takashima
Toshikazu Ushijima
Yoshinori Ito
Jun Itami
Narikazu Boku
Publication date
01-06-2020
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 6/2020
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-020-01652-7

Other articles of this Issue 6/2020

International Journal of Clinical Oncology 6/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine